Imaging software developer Median Technologies plans to highlight results of a study on the use of CT to monitor hepatocellular carcinoma lesions at the upcoming American Association for Cancer Research (AACR) annual meeting in New Orleans.
Hepatocellular carcinoma is the most common primary liver cancer, and in clinical trials, CT is widely used to monitor these patients.
The study investigated the causes of interreader variability in evaluating the therapeutic response of hepatocellular carcinoma when relying on a modified Response Evaluation Criteria in Solid Tumors (mRECIST) protocol. Researchers found that the modified procedure is best handled by experienced clinicians, and that a second reading is recommended, Median said.
